Arabinoxylan rice bran (MGN-3) enhances the effects of interventional therapies for the treatment of hepatocellular carcinoma: a three-year randomized clinical trial.

This study examined the efficacy of arabinoxylan rice bran (MGN-3) in conjunction with an interventional therapy (IT) for the treatment of hepatocellular carcinoma patients.
A total of sixty-eight patients with hepatocellular carcinoma (stages I and II) participated in the study. Patients were randomized to receive IT (30 patients, control group) or IT+MGN-3 (38 patients), and randomly divided into two groups using a computer-generated randomization list. Patients and investigators were blinded. IT included transarterial oily chemoembolization (TOCE) or a combination of TOCE and percutaneous ethanol injection treatment (PEIT).
Patients in the IT+MGN-3 group showed: (i) lower recurrence of the disease, 31.6% (12/38), as compared to 46.7% (14/30) for the control; (ii) higher survival after the second year, 35%, as compared to 6.7% for the control; (iii) significantly lower alpha-fetoprotein level, a 38% decrease (p = 0.0001), as compared to baseline value, while the control showed no significant change; and (iv) a significant decrease in tumor volume, in contrast to the control, which showed no significant change. When the results were analyzed according to each IT modality, MGN-3+IT sub-groups displayed a greater response to treatment, in every aspect examined, than the IT sub-groups alone. However, the patients in the MGN-3+TOCE+PEIT sub-group demonstrated greater reduction in AFP levels and longer survival time than the MGN-3+TOCE sub-group.
MGN-3 in conjunction with IT may be useful for the treatment of hepatocellular carcinoma and warrants further investigation in multiple clinical trials.
AuthorsMai Hong Bang, Tran Van Riep, Nguyen Tien Thinh, Le Huu Song, Trinh Tuan Dung, Le Van Truong, Le Van Don, Thai Doan Ky, Deyu Pan, Magda Shaheen, Mamdooh Ghoneum
JournalAnticancer research (Anticancer Res) Vol. 30 Issue 12 Pg. 5145-51 (Dec 2010) ISSN: 1791-7530 [Electronic] Greece
PMID21187503 (Publication Type: Journal Article, Randomized Controlled Trial)
Chemical References
  • Xylans
  • alpha-Fetoproteins
  • polysaccharide MGN3
  • Ethanol
  • Ethiodized Oil
  • Doxorubicin
  • Administration, Cutaneous
  • Adult
  • Aged
  • Aged, 80 and over
  • Carcinoma, Hepatocellular (drug therapy, pathology, surgery, therapy)
  • Catheter Ablation
  • Chemoembolization, Therapeutic (methods)
  • Double-Blind Method
  • Doxorubicin (administration & dosage)
  • Ethanol (administration & dosage)
  • Ethiodized Oil (administration & dosage)
  • Female
  • Humans
  • Liver Neoplasms (drug therapy, pathology, surgery, therapy)
  • Male
  • Middle Aged
  • Neoplasm Recurrence, Local (pathology)
  • Neoplasm Staging
  • Xylans (administration & dosage)
  • alpha-Fetoproteins (metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: